129 related articles for article (PubMed ID: 18520245)
1. AEG I and II: is it one tumor entity?
Lenglinger J; Ringhofer C; Riegler M
Ann Surg; 2008 Jun; 247(6):1080-1; author reply 1081. PubMed ID: 18520245
[No Abstract] [Full Text] [Related]
2. Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome.
Siewert JR; Lordick F; Ott K; Stein HJ; Weber WA; Becker K; Peschel C; Fink U; Schwaiger M
Ann Surg; 2007 Oct; 246(4):624-8; discussion 628-31. PubMed ID: 17893499
[TBL] [Abstract][Full Text] [Related]
3. En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma.
Rizzetto C; DeMeester SR; Hagen JA; Peyre CG; Lipham JC; DeMeester TR
J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1228-36. PubMed ID: 18544359
[TBL] [Abstract][Full Text] [Related]
4. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
Elsaleh H; Farrell JJ; Crane CH
J Gastroenterol Hepatol; 2009 May; 24(5):708-10. PubMed ID: 19646012
[No Abstract] [Full Text] [Related]
5. Oesophagectomy for tumours and dysplasia of the oesophagus and gastro-oesophageal junction.
Epari K; Cade R
ANZ J Surg; 2009 Apr; 79(4):251-7. PubMed ID: 19432710
[TBL] [Abstract][Full Text] [Related]
6. Adenocarcinoma of the esophagogastric junction: competition between Barrett and gastric cancer.
Siewert JR; Feith M
J Am Coll Surg; 2007 Oct; 205(4 Suppl):S49-53. PubMed ID: 17916519
[No Abstract] [Full Text] [Related]
7. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.
Weber MA; Bender K; von Gall CC; Stange A; Grünberg K; Ott K; Haberkorn U; Kauczor HU; Zechmann C
J Gastrointestin Liver Dis; 2013 Mar; 22(1):45-52. PubMed ID: 23539390
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy in Barrett's carcinoma - prognosis and response prediction.
Schauer M; Knoefel WT
Anticancer Res; 2010 Apr; 30(4):1065-70. PubMed ID: 20530410
[TBL] [Abstract][Full Text] [Related]
9. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of oesophageal cancer.
Veuillez V; Rougier P; Seitz JF
Best Pract Res Clin Gastroenterol; 2007; 21(6):947-63. PubMed ID: 18070697
[TBL] [Abstract][Full Text] [Related]
10. [Adenocarcinoma of the Barrett esophagus. Apropos of 44 resected cases].
Lozac'h P; Topart P; Volant A
J Chir (Paris); 1997 Nov; 134(5-6):218-26. PubMed ID: 9772976
[No Abstract] [Full Text] [Related]
11. Adenocarcinoma of the esophagogastric junction: the pattern of metastatic lymph node dissemination as a rationale for elective lymphatic target volume definition.
Meier I; Merkel S; Papadopoulos T; Sauer R; Hohenberger W; Brunner TB
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1408-17. PubMed ID: 18374226
[TBL] [Abstract][Full Text] [Related]
12. [New classification for adenocarcinoma of the esophagogastric junction in China].
Bai JG; Dang CX
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):138-43. PubMed ID: 17344604
[TBL] [Abstract][Full Text] [Related]
13. Locally advanced rectal cancer patients receiving radio-chemotherapy: a novel clinical-pathologic score correlates with global outcome.
Berardi R; Mantello G; Scartozzi M; Del Prete S; Luppi G; Martinelli R; Fumagalli M; Grillo-Ruggieri F; Bearzi I; Mandolesi A; Marmorale C; Cascinu S
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1437-43. PubMed ID: 19386440
[TBL] [Abstract][Full Text] [Related]
14. [Preoperative neoadjuvant chemotherapy in esophago-cardial adenocarcinoma?].
Geissler M
Dtsch Med Wochenschr; 2006 Jun; 131(23):1344. PubMed ID: 16761207
[No Abstract] [Full Text] [Related]
15. [Neoadjuvant therapy in the upper gastro-intestinal tract. Modern strategies for Barrett's cancer].
Stein HJ; Feith M; Siewert JR
Chirurg; 2009 Nov; 80(11):1019-22. PubMed ID: 19902287
[TBL] [Abstract][Full Text] [Related]
16. Role of neoadjuvant therapy for esophageal adenocarcinoma.
Ku GY; Ilson DH
Surg Oncol Clin N Am; 2009 Jul; 18(3):533-46. PubMed ID: 19500742
[TBL] [Abstract][Full Text] [Related]
17. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
[TBL] [Abstract][Full Text] [Related]
18. [Effectiveness of postoperative radio- and chemotherapy in N(+) esophageal carcinoma].
Sack H
Strahlenther Onkol; 2002 Feb; 178(2):109-10. PubMed ID: 11942034
[No Abstract] [Full Text] [Related]
19. Neoadjuvant chemoradiotherapy in esophageal cancer: is it still the question?
Pereira B; Gourgou-Bourgade S; Azria D; Ychou M
J Clin Oncol; 2008 Nov; 26(31):5133-4; author reply 5134. PubMed ID: 18838699
[No Abstract] [Full Text] [Related]
20. Neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: prognostic value of circumferential resection margin and stratification of N1 category.
Saha AK; Sutton C; Rotimi O; Dexter S; Sue-Ling H; Sarela AI
Ann Surg Oncol; 2009 May; 16(5):1364-70. PubMed ID: 19252949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
